H.C. Wainwright Reaffirms Vertex Pharmaceuticals (NASDAQ:VRTX) As a “Buy”; They Now Have a Target Price per Share Of $220.0000

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Investors sentiment increased to 1.3 in 2018 Q2. Its up 0.15, from 1.15 in 2018Q1. It increased, as 34 investors sold Vertex Pharmaceuticals Incorporated shares while 176 reduced holdings. 61 funds opened positions while 211 raised stakes. 236.55 million shares or 1.64% more from 232.72 million shares in 2018Q1 were reported.

Washington Co holds 13 shares. Moreover, Verition Fund Limited Liability Corp has 0.08% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hanson Mcclain holds 0% or 26 shares. Dorsey Wright Associate has 0.41% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 16,510 shares. Envestnet Asset Mngmt owns 26,553 shares or 0.01% of their US portfolio. Quantbot Techs Limited Partnership has invested 0.29% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Elk Creek Prtnrs Ltd Llc stated it has 3,790 shares. State Board Of Administration Of Florida Retirement Sys reported 0.16% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Raymond James Na owns 4,475 shares. Schwab Charles Invest Mgmt Incorporated reported 907,208 shares. Cibc Markets has 0.08% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 56,633 shares. Moreover, Mason Street Advsr Ltd Liability Corporation has 0.14% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 35,753 shares. Bb&T has 0.03% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). California State Teachers Retirement Systems invested in 0.14% or 407,844 shares. Wellington Mgmt Llp holds 10.31M shares or 0.39% of its portfolio.

Since June 1, 2018, it had 0 insider buys, and 29 selling transactions for $44.72 million activity. Arbuckle Stuart A also sold $4,749 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. The insider Silva Paul M sold 860 shares worth $154,671. LEIDEN JEFFREY M sold $22.43 million worth of stock or 140,211 shares. ALTSHULER DAVID also sold $4.25 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, July 16. $2.48 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit on Friday, July 13. Kewalramani Reshma also sold $430,920 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares.

Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Reaffirmed

In an analyst report published on Wednesday, 28 November, The “Buy” rating of Vertex Pharmaceuticals (NASDAQ:VRTX) shares was reconfirmed at H.C. Wainwright, who now has a $220.0000 price target on the stock. H.C. Wainwright’s price target would indicate a possible upside of 21.69 % from the previous close of the company.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 7 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Vertex Pharmaceuticals has $220 highest and $188 lowest target. $205’s average target is 13.39% above currents $180.79 stock price. Vertex Pharmaceuticals had 9 analyst reports since July 26, 2018 according to SRatingsIntel. Morgan Stanley maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, July 26. Morgan Stanley has “Overweight” rating and $211 target. The company was maintained on Thursday, July 26 by UBS. The stock has “Buy” rating by H.C. Wainwright on Friday, October 26. The rating was maintained by Raymond James on Thursday, October 25 with “Outperform”. On Monday, July 30 the stock rating was maintained by Citigroup with “Buy”. The firm earned “Buy” rating on Wednesday, November 28 by H.C. Wainwright. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by BMO Capital Markets on Thursday, October 25.

The stock increased 0.75% or $1.34 during the last trading session, reaching $180.79. About 1.10 million shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 13.72% since December 2, 2017 and is uptrending. It has underperformed by 1.90% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $46.20 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 72.23 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down – Nasdaq” on November 08, 2018, also Nasdaq.com with their article: “Market Close Report: NASDAQ Composite index closes at 7,082.70 up .85 points – Nasdaq” published on November 27, 2018, Seekingalpha.com published: “Long-Term Outlook For Vertex Pharmaceuticals: October 13, 2018 – Seeking Alpha” on October 14, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Globenewswire.com and their article: “Analysis: Positioning to Benefit within Vertex Pharmaceuticals, MISONIX, Whiting Petroleum, Kewaunee Scientific, Arotech, and Apollo Commercial Real Estate Finance — Research Highlights Growth, Revenue, and Consolidated Results – GlobeNewswire” published on November 14, 2018 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 11/27/2018: VRTX,HALO,GTHX,ACAD – Nasdaq” with publication date: November 27, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.